Review Article

Tramadol/Paracetamol Fixed-Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review

Ignacio Morón Merchante, 1 Joseph V. Pergolizzi Jr., 2, 3 Mart van de Laar, 4 Hans-Ulrich Mellinghoff, 5 Srinivas Nalamachu, 6, 7 Joanne O’Brien, 8 Serge Perrot, 9 and Robert B. Raffa 10

1 Centro de Salud Universitario Goya, c/O’Donnell 55, 28009 Madrid, Spain
2 Johns Hopkins University, Baltimore, MD 21287, USA
3 Association of Chronic Pain Patients, Houston, TX 77515, USA
4 Arthritis Center Twente (MST & UT), P.O. Box 50 000, 7500 KA Enschede, The Netherlands
5 Department of Endocrinology, Diabetology and Osteology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
6 Kansas University Medical Center, Kansas City, KS 66160, USA
7 International Clinic Research, Overland Park, KS 66210, USA
8 Department of Pain Medicine, Beaumont Hospital, Beaumont, Dublin 9, Ireland
9 Service de Médecine Interne et Consultation de la Douleur, Hôpital Dieu, 75004 Paris, France
10 Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140, USA

Correspondence should be addressed to Ignacio Morón Merchante; moron@movistar.es

Received 30 January 2013; Accepted 19 February 2013

Academic Editors: D. Fung and C. Pearce

Copyright © 2013 Ignacio Morón Merchante et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The family practitioner plays an important role in the prevention, diagnosis, and early management of chronic pain. He/she is generally the first to be consulted, the one most familiar with the patients and their medical history, and is likely the first to be alerted in case of inadequate pain control or safety and tolerability issues. The family practitioner should therefore be at the center of the multidisciplinary team involved in a patient’s pain management. The most frequent indications associated with chronic pain in family practice are of musculoskeletal origin, primarily affecting the back and joints (Figures 1 and 2) [1, 4].

Chronic pain affects quality of life and personal relationships and is often accompanied by depression, sleep disorders, and also low self-esteem [4]. In addition to the immense

1. Introduction

One of the major reasons for patients presenting at a primary care practice is pain; according to surveys, around 40% of patients consult their family doctor mainly owing to pain, and 20–40% of those have been suffering from pain for more than 6 months [1, 2]. High prevalence rates for chronic pain have been reported in many countries [3–10]; for example, 20% of the European population are suffering from moderate-to-severe chronic pain (1-month prevalence, excluding cancer pain [3]). In the majority of cases (70%) the family practitioner is looking after these patients [4]. The most frequent indications associated with chronic pain in the family practice are of musculoskeletal origin, primarily affecting the back and joints (Figures 1 and 2) [1, 4].

Chronic pain affects quality of life and personal relationships and is often accompanied by depression, sleep disorders, and also low self-esteem [4]. In addition to the immense
A consensus meeting of pain specialists from different fields was held in November 2010 in Paris, France, in order to review and discuss the management of moderate-to-severe chronic pain with special emphasis on the use of paracetamol, NSAIDs, and tramadol/paracetamol as an example for fixed-dose combination analgesics. Discussions about available treatment options for chronic pain management and current guidelines and treatment recommendations for various conditions and patient populations were continued after the meeting; the final consensus on pain management options for pain indications frequently seen by a family practitioner is presented in this paper.

2. Pain Assessment

Chronic pain can be categorized as nociceptive pain (caused by tissue damage or disease), neuropathic pain (caused by damage or disease of the peripheral or central nervous system), or mixed pain with both nociceptive and neuropathic components [15]. In addition, the location of pain may differ from the site of origin of pain, as is the case with referred pain and radicular pain. Successful pain management initially requires a thorough diagnostic work-up, through patient history, physical examination, and diagnostic tests in order to identify

(i) the location and cause of pain;
(ii) the frequency with which the pain occurs and potential exacerbating and relieving factors;
(iii) previous treatment received by patient, and its efficacy;
(iv) the severity of pain, and its quality (e.g., dull, aching, stabbing, lancinating, burning, etc.);
(v) the chronification stage of pain;
(vi) the impact of pain on the patient (e.g., quality of life, loss of productivity), his/her family or caregivers.

Initial pain assessment should also include documentation of pain frequency (continuous, intermittent, or continuous with intermittent flares), of presence or absence of triggers, and of presence or absence of somatosensory abnormalities such as increased or decreased perception of stimuli (e.g., hypo- or hyperalgesia, allodynia, or numbness).

Simple scores should be used to assess pain intensity in order to monitor the progression/improvement of pain with a time-saving method during the family practitioner visit. Pain intensity is usually assessed using 11-point rating scales with 0 indicating “no pain” and 10 indicating “worst imaginable pain” or along a 100 mm horizontal line, with ratings measured from the left edge (Table 1). Visual analogue (VAS) and numerical (NRS [16]) and verbal (VRS) rating scales are available both for the assessment at the family practice and for patients’ self-assessments. In addition, Wong-Baker FACES scales (Figure 3 [17]) are used for children and adults who are unable to communicate their pain such as patients with cognitive impairment. Pain intensity assessments are widely used as efficacy parameters for a given medication, both in clinical trials and in clinical practice.
Table I: Instruments for the assessment of pain and pain-related quality of life.

| Questionnaire                                      | Assessments                                                                 | Scoring                                                                 |
|----------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Pain scales, for example;                          |                                                                             | Self-assessment and physician assessment                                |
| (i) numerical scales (NRS) [16]                    | Assessment of pain intensity                                                | 11-point or 100 mm scales                                              |
| (ii) visual analogue scales (VAS)                  |                                                                             | 0 = no pain to 10 = worst imaginable pain                              |
| (iii) verbal rating scales (VRS)                   |                                                                             |                                                                       |
| (iv) Wong-Baker FACES scales [17]                  |                                                                             |                                                                       |
| CHANGE PAIN scale [33]                             |                                                                             |                                                                       |
| (i) 11-point NRS on the front                      | Assessment of pain intensity                                                | 11-point scale with 0 = no pain to 10 = worst imaginable pain          |
| (ii) 6 key parameters affecting quality of life on | Setting individual treatment goals for the patients                        | Need for improvement: not at all, a little, very much                  |
| the back                                           |                                                                             |                                                                       |
| SF-36-Health Survey [28]                           | Measures general health status including physical functioning, role-physical| 8 items are rated on a scale ranging from 0 to 100; higher values      |
|                                                   | bodily pain, general health, vitality, social functioning, role-emotional, | indicate a better outcome. A frequently used shorter version is the    |
|                                                   | and mental health                                                          | SF-12 [34]                                                             |
| SF-MPQ model (Short Form McGill Pain Questionnaire | Pain assessment with a short form of the McGill Pain Questionnaire          |                                                                       |
| (SF-MPQ) [35]                                      | It includes the Present Pain Intensity (PPI) of the standard MPQ and a visual |                                                                       |
|                                                   | analogue scale (VAS).                                                      |                                                                       |
| BPI [36]                                           | Measures pain (including presence of pain, localization, pain intensity,    | Self-assessment                                                         |
|                                                   | pain medication, and pain reduction during defined time frame) and         | Short version contains 9 questions scored on an 11-point scale ranging  |
|                                                   | impairments of daily life                                                  | from 0 = no pain/no impairment to 10 = as bad as you can imagine       |
| EuroQol (EQ-5D) [37]                               | Assessment of pain, quality of life, and daily functioning                  |                                                                       |
| Depression, Anxiety, and Stress Scale              | Assessment of depression, anxiety, and stress                              | Self-assessment                                                         |
| (DASS) [29]                                        |                                                                             | Three subscales with 14 items, rated on a four-point Likert scale       |
|                                                   |                                                                             | (total scores from 0 to 42 on each subscale)                           |
|                                                   |                                                                             | Depression: scores above 20 indicate severe depression                 |
|                                                   |                                                                             | Anxiety: scores above 14 indicate severe anxiety                      |
|                                                   |                                                                             | Stress: scores above 25 indicate severe stress                         |
| WOMAC Osteoarthritis Index [31, 32]                | Sensory pain description and assessment of affective pain experience       | Patient self-assessment                                                |
|                                                   |                                                                             | 24 questions in three domains: pain, disability, and joint stiffness   |
|                                                   |                                                                             | Answers are scored on a 5-point Likert scale or 100 mm visual          |
|                                                   |                                                                             | analogue scale with higher scores indicating greater difficulty       |
For a comprehensive diagnosis of chronic pain, a determination of pain type is also necessary and should include the use of neuropathic pain assessment tools such as pain DETECT [18], DN4 (Douleur Neuropathique en 4 questions [19], Table 2), or LANSS (Leeds Assessment of Neuropathic Symptoms and Signs [20]), which have been validated in several languages. The assessment of neuropathic pain in primary care has recently been extensively reviewed [21].

One way of defining pain as chronic has been on the basis of its duration, that is, if it lasts for more than 3 or 6 months [22, 23]; however, a standard, internationally accepted definition for chronic pain is not available. In Germany, chronicity staging with the validated Mainz Pain Staging System [24] is part of the German Pain Questionnaire, a standardized and validated tool for chronic pain therapy [25]. The three stages—I (at risk of chronification), II (chronification), and III (marked chronification)—indicate the progression of the disease. Currently, attempts are underway to include psychological and behavioral factors in a definition of chronic pain, with the objective of including all aspects of a patient's pain in an integrated pain management strategy [26]. The assessment of chronicity is important in order to assess the risk of future chronic pain in a given patient and to rapidly initiate adequate pain management [26].

Initial and follow-up pain intensity assessments are essential but not sole indicators for successful or unsuccessful treatment. Other factors such as improved mobility or independence of the patient, working ability, improved coping and psychological status, and overall quality of life might be equally important to the patient (see the following).

3. Pain-Related Comorbidities and Quality of Life

Chronic pain has an enormous impact on quality of life and daily activities of the patient. It affects sleep in the majority of patients, impairs physical activities, the ability to attend to household chores, and employed work, and restricts many patients in terms of relationships and social activities [27]. Additional burden arises for the patient through pain-related comorbidities such as depression and anxiety. According to a recent survey among chronic pain patients with moderate-to-severe pain (defined as pain ≥5 on an 11-point scale for six months or more) in the European Union, 21% had been diagnosed with pain-related depression [4]. Whereas pain treatment in the past primarily targeted the reduction of pain intensity, maintaining or improving quality of life of the patients is increasingly being recognized as an equally important goal. Thus, in addition to the diagnosis of pain, quality of life parameters and pain-related comorbidities ought to be assessed and taken into consideration in treatment decisions. Some examples for commonly used assessment tools are given in Table 1; many international tools have been translated and validated in various languages. In addition to overall quality of life questionnaires such as the SF-36-Health Survey [28], scales determining depression, anxiety, and stress [29, 30], and disease-specific tools such as the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index [31, 32] have been developed. Recently, the CHANGE PAIN scale was introduced, a simple tool easy to use in primary practice, which can initially be used to record pain intensity and define individual treatment goals but can subsequently determine patient-centered perceptions of change [33].

Given primary practice reality with a short-time frame available for each individual patient, many physicians may shy away from the extra time spent in completing and evaluating additional questionnaires. However, these tools may enable a more efficient and thus in the long-term time-saving approach. In particular, focusing on the patient's individual needs may reduce a substantial burden for the patient and avoid long periods of unnecessary suffering owing to unsuitable treatment approaches.

4. Pain Management by Family Practitioners

The family practitioner plays an important role in the prevention, diagnosis, and early management of chronic pain. He/she is usually the physician who is most familiar with the patient and his/her medical history, keeps an overview on the various therapies prescribed by him-/herself and other specialists, and is likely to be the first to be alerted in the case of inadequate pain control or if safety issues owing to comorbidities or comedications arise. Since the family
practitioner usually also builds a trusting relationship with the patient, the patient is most likely to disclose concerns, potential side effects of medications, effects of the treatments/pain on his/her daily life and social network, and so forth. The family practitioner might be able to identify unmet needs of the patient, requirements for patient information, and education and potential requirements to involve the family/partners in the overall treatment plan and care. For many indications, in particular musculoskeletal diseases, a multimodal treatment approach combining both nonpharmacological and pharmacological treatments will likely lead to the best outcome in terms of pain relief and improvement of quality of life. The family practitioner should be at the core of a multidisciplinary team for pain management including, for example, pain specialists, physiotherapists, and others. Nonpharmacological treatments may include changes in diet, weight loss, changes in lifestyle, exercise, or massage that can be easily accessible to primary care physicians. Other options like acupuncture, thermotherapy, transcutaneous electrical nerve stimulation (TENS), surgery, and many others are beyond the scope of this paper. This section will focus on general considerations concerning available pharmacological treatment options.

### 4.1. Paracetamol

Paracetamol (also known as acetaminophen or APAP) is a very popular medication, which is available over-the-counter as well as in prescription medications. It has analgesic and antipyretic but, unlike nonsteroidal anti-inflammatory drugs, no confirmed anti-inflammatory properties, although there have been studies pointing to some anti-inflammatory effects [38, 39]. Its exact mode of action is still poorly understood and several mechanisms have been proposed, which seem to point to a largely central effect [40]. In healthy individuals, a daily maximum dose of 4 g is considered relatively safe [41], given a considerable interindividual variability. However, certain conditions such as chronic alcohol abuse, malnutrition, existing liver disease, and concurrent use of drugs, which induce cytochrome P450 enzymes, can lead to hepatotoxicity even at therapeutic dosages [42]. In Europe and North America, a large proportion of cases of acute liver failure are due to paracetamol [43]. Paracetamol overdoses are often unintentional [42] and likely occur because many patients are unaware of the fact that their “harmless” cold remedies or headache tablets can also contain paracetamol. Patients therefore need to be properly educated if paracetamol-containing medications are prescribed.

### 4.2. NSAIDs

NSAIDs are very effective drugs with anti-inflammatory, and analgesic efficacy rendering them useful for many acute pain conditions. They are widely used over-the-counter and prescription products and are contained in many combination formulations.

NSAIDs are associated with gastrointestinal, cardiovascular, and renal side effects and mortality with an estimated 3500 to 16,500 deaths per year due to NSAID-related gastrointestinal bleeding in USA [44]. In addition, NSAIDs also interact with many other medicinal products [45–48], and special caution and close monitoring are recommended for patients with conditions such as gastrointestinal disorders, renal, cardiac, or hepatic impairment, and hypertension and patients with a history of asthma and seasonal allergic rhinitis (since they act as bronchoconstrictors). Following the discovery of cyclooxygenase (COX)-2 and in an attempt to overcome the gastrointestinal side effects of NSAIDS, COX-2-selective NSAIDs were developed. Rofecoxib was withdrawn from the market approx. 5 years later because of

### Table 2: The DN4 questionnaire (Douleur Neuropathique en 4 questions) to estimate the probability of neuropathic pain [19].

| Interview of the patient |
|--------------------------|
| **Question 1:**  |
| Does the pain have one or more of the following characteristics? | Yes | No |
| Burning | ☐ | ☐ |
| Painful cold | ☐ | ☐ |
| Electric shocks | ☐ | ☐ |
| **Question 2:**  |
| Is the pain associated with one or more of the following symptoms in the same area? | Yes | No |
| Tingling | ☐ | ☐ |
| Pins and needles | ☐ | ☐ |
| Numbness | ☐ | ☐ |
| Itching | ☐ | ☐ |
| Examination of the patient |
| **Question 3:**  |
| Is the pain located in an area where the physical examination may reveal one or more of the following characteristics? | Yes | No |
| Hypoesthesiatotouch | ☐ | ☐ |
| Hypoesthesiatopinprick | ☐ | ☐ |
| **Question 4:**  |
| In the painful area, can the pain be caused or increased by | Yes | No |
| Brushing? | ☐ | ☐ |
cardiovascular risks, shortly followed by warnings and dose restrictions for all NSAIDs.

Owing to these safety issues, all NSAIDs should be used for the shortest possible duration at the lowest effective dose. In the elderly in particular, NSAIDs should be used “rarely and with extreme caution in highly selected individuals” [49]. In general, NSAIDs are not suitable for long-term treatment of chronic pain conditions.

4.3. Opioids. Opium has been used since antiquity for treating pain. In modern times, synthetic opioids have been added to the naturally derived compounds. Some of the side effects and special issues related to opioids might restrict their long-term use, at least in some patients [50]. Constipation is a frequent problem requiring comedication for most strong opioids [51]. In addition, respiratory depression is likely to cause problems in special patient groups, such as asthmatics and cardiovascular patients with impaired lung function.

Opioids are associated with different levels of tolerance, dependence, and addiction potential. These are three distinct phenomena. Tolerance describes the state in which a patient requires increasingly higher doses of the opioid to achieve the same level of pain relief. In some cases, tolerance is a normal response to opioid therapy; it can sometimes be managed by opioid rotation, that is, switching to other opioids [52]. Manifestations of opioid-induced hyperalgesia mimic tolerance [53]. A patient with opioid-induced hyperalgesia should, however, be tapered off opioids, whereas a patient with tolerance may require a judicious and supervised increase of the opioid dose [53]. Dependence occurs when discontinuation of the substance results in withdrawal symptoms; dependence is a normal and expected result of long-term opioid therapy and is typically managed by tapering the drug rather than abruptly stopping it [54]. Addiction has been defined as the continuing use of a substance (or behaviour) despite adverse consequences to the user [55]. Opioid-addicted patients are dependent, but not all opioid-dependent patients are addicted. A newer term in use is “inappropriate use of opioid,” a continuum of behaviors involving the intentional or inadvertent misuse of opioids, particularly prescribed opioids [56]. A variety of opioid analgesic products have been designed in abuse-deterrent or abuse-resistant formulations, aimed at making it more difficult to tamper with the products [57, 58].

However, these dangers are frequently overestimated, and opioids are often the only choice for severe pain and can be a good choice for special patient groups such as the elderly. They also present an alternative when long-term NSAID treatment is not recommended. The transdermal formulations of fentanyl and buprenorphine in particular appear to be effective with low toxicity and good tolerability profiles, especially at low doses [59].

4.4. Tramadol. Tramadol has been on the market since 1977 and is considered a type of opioid. However, it is different from most other opioids because of its multiple mechanism of analgesic action (binding to \( \mu \)-opioid receptors and inhibition of neuronal reuptake of norepinephrine and serotonin) [60, 61]. Tramadol has been shown to be effective in different acute and chronic pain states [62, 63]; its extended-release formulations are thought to be particularly suitable for long-term treatment of multmechanistic pain conditions such as osteoarthritis, low back pain, and neuropathic pain [64]. Tramadol has no known anti-inflammatory effects.

Side effects include nausea, vomiting, dizziness, sweating, and dry mouth; reports of drug dependence and abuse are rare [65]. Isolated cases of serotonin syndrome have been reported during concomitant use of tramadol in combination with other serotoninergic medicinal products such as selective serotonin reuptake inhibitors (SSRIs) or with MAO inhibitors [65]. Unlike other opioids, tramadol has no clinically relevant effects on respiratory or cardiovascular parameters at recommended doses [66]. For chronic pain, 50 mg or 100 mg tramadol is administered every 4 to 6 h, with a total daily dose not in excess of 400 mg; the dosage interval should be extended in elderly patients and patients with renal or hepatic impairment [65].

4.5. Topical Analgesics. Topical analgesics are an important pain management option which provides localized pain relief. Overall, this group is efficacious with a good safety profile [67]. Due to reduced or no systemic action, the risk of systemic side effects is markedly reduced which might increase patient compliance, safety, and quality of life. Typical side effects include skin irritations which are often mild. Most topical analgesics are available as patches, ointments, or creams [67], many as over-the-counter products. Examples are the 5% lidocaine medicated plaster [68], topical NSAIDs [69], and the 8% capsicain patch [70].

4.6. Anticonvulsants. The clearest evidence for the efficacy of anticonvulsants in pain relief was found in patients suffering from neuropathic pain [71]. Several mechanisms of action have been reported for anticonvulsants, among them the blockage of voltage-gated calcium channels (gabapentin, pregabalin, etc.) and the blockage of voltage-gated sodium channels (carbamazepine, oxcarbazepine, lamotrigine, lacosamide, etc.) [72].

Dose-related side effects occur with all anticonvulsants; the majority are CNS related (i.e., somnolence, dizziness, ataxia, and headache) [72]. There are also specific, sometimes significant adverse reactions depending on the prescribed anticonvulsant such as hyponatremia, leukopenia, thrombocytopenia and hepatotoxicity for carbamazepine and weight gain, and blurred vision and edema for gabapentin and pregabalin [71].

4.7. Antidepressants. There is evidence of antidepressant analgesia independent of their effect on depression or other psychiatric disorders [73]. Tricyclic antidepressants (TCAs) provide pain relief in a variety of conditions but are associated with side effects such as sedation, dizziness, blurred vision, constipation, and dry mouth, which can be treatment limiting. Cardiac toxicity is a concern, and it is recommended to prescribe TCAs with caution in patients with ischemic cardiac disease or ventricular conduction abnormalities [74]. Amitriptyline and other tertiary TCAs are listed on the
recently revised Beers list of potentially inappropriate medication use in older adults with a strong recommendation to avoid their use because they are highly anticholinergic, sedating and cause orthostatic hypotension [75].

The selective serotonin norepinephrine reuptake inhibitors (SNRIs), duloxetine and venlafaxine, are first-line treatments for neuropathic pain, and duloxetine and milnacipran are recommended for fibromyalgia treatment. Overall, they are better tolerated than TCAs with nausea as the main side-effect. Caution is advised for venlafaxine in patients with cardiac disease [74].

4.8. Glucocorticoids. Glucocorticoids have clinically important anti-inflammatory and immunosuppressive effects which are, among others, used in the treatment of rheumatic diseases [76]. Safety concerns for higher doses or long-term treatment include amongst others glucocorticoids-induced osteoporosis and risk of fracture [77], immunosuppression [78], increased risk of infections, weight gain, leg edema, thinning skin, Cushing’s syndrome, hypertension, glaucoma, cataracts, shortness of breath, and sleep disturbances [79], and the onset or worsening of diabetes [80]. Patients with established rheumatoid arthritis should be made aware of long-term complications with glucocorticoids and all other treatment options should be offered before glucocorticoid treatment is maintained in the long-term [81].

4.9. Combination Products. Since most pain conditions involve more than one underlying pain generating process and pain is transmitted via a large number of different pathways, a practical treatment approach is using drugs or drug combinations with different mechanisms of action and thus different targets. However, not all combinations are ideal because a combination of two or more individual compounds may lead to additive or even synergistic analgesic effects but might also lead to a higher than anticipated side-effect rate. Thorough testing of combinations and determining the right dose ratio of the individual components are therefore required. A recent review covers these issues in detail [61].

Fixed-dose combination analgesic products reduce the pill burden and may require lower dosages than the individual compounds. They are, however, inflexible, and doses may not be ideal for particular patients. Many fixed-dose combination analgesics contain paracetamol, and patients may exceed the recommended daily paracetamol intake of 4 g for healthy adults [41]. Family practitioners need to educate their patients on this issue.

Fixed-dose combinations with an opioid include codeine/paracetamol, oxycodone/paracetamol, tramadol/paracetamol, and others. These products may be opioid sparing, because they provide effective analgesia at lower opioid doses than opioids taken in monotherapy. This was shown in two studies comparing tramadol/paracetamol with tramadol monotherapy in the management of subacute low back pain [82] and pain following ambulatory hand surgery with iv regional anesthesia [83]. Fixed-dose combination treatment reduced tramadol consumption by 24% in both studies and resulted in significantly fewer side effects than with tramadol monotherapy.

Analgesic synergy of fixed-dose combination products for pain relief in humans has, to our knowledge, so far only been demonstrated for tramadol/paracetamol [84]. Details concerning the experience with this combination are given below for individual indications.

5. Pain Indications Frequently Encountered by the Family Practitioner

This section lists the most common chronic pain indications encountered by the family practitioner and available treatment guidelines/recommendations for the individual indications. A summary of the studies investigating treatment with tramadol/paracetamol for a given indication is included.

Table 3 summarizes the design of the studies mentioned below.

5.1. Musculoskeletal Pain. The majority of chronic pain patients in primary care suffer from musculoskeletal pain [1]. Indications reviewed separately below are osteoarthritis, low back pain, and rheumatoid arthritis. Three studies assessed tramadol/paracetamol for musculoskeletal pain of different origins and are discussed here [85–87]. The two latter studies are of particular interest to the family physician because they observed pain management in the clinical practice setting.

The efficacy and tolerability of tramadol/paracetamol were compared to codeine/paracetamol in adult patients with chronic nonmalignant low back pain, osteoarthritis pain, or both [85]. At baseline, three-quarters of patients in both treatment groups presented with at least moderate pain. Pain relief was comparable between treatments and associated with a similar incidence of overall adverse events except for somnolence (24% versus 17%; \( P = 0.05 \)) and constipation (21% versus 11%; \( P < 0.01 \)), which was more common for codeine/paracetamol treatment. Patients completing this study could participate in an 23-month open-label extension study [88]. They received a mean daily tramadol/paracetamol dose of 157 mg/1363 mg. Pain relief was maintained during the extension period. Overall treatment efficacy was rated very good or excellent by 39% of the patients and 40% of the physicians. Twenty-four percent of the patients discontinued prematurely due to adverse events.

The ELZA study assessed efficacy and safety of tramadol/paracetamol in 5495 patients aged over 12 years who presented with moderate-to-severe pain (for more than 3 months in 15.6% of the patients) to general practitioners in France [86]. The most common origin of pain was musculoskeletal (24.9% osteoarthritis, 20.1% low back pain, and 13.9% spinal nerve root compression). Treatment reduced the mean pain intensity at baseline from 6.3 ± 1.7 (11-point NRS scale) to 2.3 ± 1.9 at final assessment (\( P < 0.001 \)). Quality of sleep improved in 54.9% of all patients. A total of 4.2% of the patients reported adverse events, most commonly gastrointestinal disorders.

The SALZA study assessed the clinical benefits of tramadol/paracetamol in 2663 patients aged ≥65 years with moderate-to-severe pain in French general practices [87]. The most common origin of pain was musculoskeletal (59.1%
| Study            | Type                                                                 | Patients                                                                 | Tramadol/paracetamol mean daily dose | Comparator mean daily dose |
|------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------|---------------------------|
| **Musculoskeletal pain** |                                                                      |                                                                          |                                      |                           |
| Mullican and Lacy, 2001 [85] | 4-week double-blind, double-dummy, active-control, multicenter, randomized | 462 Mean age 57.6 years Chronic nonmalignant low back pain, osteoarthritis pain, or both | 131 mg/1133 mg                    | Codeine/paracetamol 105 mg/1054 mg |
| Serrie et al., 2011 [86] | Observational, prospective, open-label, in clinical practice 37.6% first-line treatment 62.4% following treatment failure of mainly paracetamol or analgesics containing dextropropoxyphene | 5495 Mean age 53.2 ± 15.9 years Mainly musculoskeletal pain | 139 mg/1203 mg Mean treatment duration 16.6 ± 9.8 days | None |
| Mejjad et al., 2011 [87] | Observational, prospective, open-label, in clinical practice 30% first-line treatment 70% after treatment failure/safety problems with at least one other analgesic | 2,663 ≥65 years old; mean age 73.6 ± 6.6 years Primarily musculoskeletal pain | 143 mg/1235 mg Mean treatment duration 23.2 ± 9.2 days | None |
| **Osteoarthritis** |                                                                      |                                                                          |                                      |                           |
| Silverfield et al., 2002 [96] | 10-day multicenter, double-blind, placebo-controlled, randomized Add-on treatment | 308 Mean age 60.1 ± 9.9 years Hip or knee flare pain | 37.5 mg/325 mg 1-2 tablets qid | Placebo |
| Emkey et al., 2004 [97] | 3-month multicenter, double-blind, randomized Add-on to celecoxib or rofecoxib Multicenter, randomized, comparative | 306 Mean age 61 ± 9 years Hip or knee pain | 154 mg/1332 mg | Placebo |
| Park et al., 2012 [98] | 8-week monotherapy after 4-week add-on to meloxicam or celecoxib | 97 Knee OA > 1 year | 121 mg/1050 mg Mean treatment duration 60 ± 7.4 years | Meloxicam or aceclofenac Mean age 61.2 ± 7.5 years |
| Choi et al., 2007 [99] | 2-week multicenter, double-blind, double-dummy add-on to NSAIDs Safety study Randomization to titration and nontitration group | 250 Mean age 60.2 ± 7.8 years Knee OA on stable NSAID therapy | 37.5 mg/325 mg tid Titration over 7 days for titration group | None |
| **Low back pain** |                                                                      |                                                                          |                                      |                           |
| Ruoff et al., 2003 [106] | 3-month double-blind, multicenter, randomized, placebo-controlled | 318 Mean age 53.9 years At least moderate chronic lower back pain | 158 mg/1365 mg | Placebo |
| Peloso et al., 2004 [107] | 3-month double-blind, multicenter, randomized, placebo-controlled | 336 Mean age 57.5 ± 12.6 years At least moderate chronic lower back pain | 158 mg/1369 mg | Placebo |
| **Rheumatoid arthritis** |                                                                      |                                                                          |                                      |                           |
| Lee et al., 2006 [108] | 1-week, double-blind, randomized, placebo-controlled Add-on treatment | 277 Inadequate pain control by conventional NSAIDs and DMARDs | 112.5 mg/975 mg Mean pain 51.6 ± 11.7 years | Placebo Mean age 52 ± 12 years |
| **Painful diabetic neuropathy** |                                                                      |                                                                          |                                      |                           |
| Freeman et al., 2007 [109] | 66-day double-blind, multicenter, randomized, placebo-controlled | 313 Mean age 55.7 ± 10.3 years 94% type 2 diabetics Neuropathy symptoms for a mean 3.7 ± 2.6 years | 158 mg/1365 mg | Placebo |
arthrosis, 33% low back pain, 16.9% spinal nerve root compression, and 15.8% other rheumatological pathologies). The mean pain intensity at baseline of 6.1 ± 1.6 (11-point NRS scale) was reduced by 3.1 points; 64.8% experienced complete pain relief, and the majority (90.5%) were satisfied with the treatment. Discontinuation of treatment due to insufficient efficacy or adverse events occurred in 1.5% and 2.5% of all patients, respectively. Adverse events were reported by 4.5% of the patients, mainly gastrointestinal disorders (4.1%). These studies show the efficacy of fixed-dose tramadol/paracetamol with a good safety profile in the treatment of chronic musculoskeletal pain both under randomized study conditions and, more importantly, in clinical practice. The clinical benefits in the elderly in particular are noteworthy and suggest tramadol/paracetamol as an alternative to conventional analgesics such as NSAIDs, which should be considered rarely with extreme caution in this population [49].

5.1.1. Osteoarthritis. Prevalence of osteoarthritis (OA) increases with advancing age; the greatest disease burden is attributable to the involvement of the hip or knee joints [89]. Pain is the overriding clinical issue [90]. Complex underlying pain mechanisms [91] might require the administration of pain medications from different medication classes to achieve sufficient analgesia.

OA management is focused on symptom control, prevention of disease progression, minimization of disability, and improvement of quality of life [92] and requires a combination of nonpharmacological and pharmacological measures. Recommendations for initial analgesic treatment include paracetamol and topical NSAIDs (for hand and knee) ahead of oral NSAIDs including COX-2 inhibitors [93–95]. The latter should be used at the lowest effective dose, and long-term use should be avoided. Weak opioids and topical capsaicin and intra-articular corticosteroid injections as an adjunct can also be considered. However, stronger opioids should only be used for severe pain in exceptional circumstances [93] or in symptomatic knee or hip OA following insufficient response to both nonpharmacological and pharmacological treatments and where patients are not suitable for total joint arthroplasty [94].

OA pain management using tramadol/paracetamol fixed-dose combination as an add-on treatment to NSAIDs or COX-2 inhibitors or as monotherapy was investigated in four studies [96–99]. Adding the fixed-dose combination to the treatment regimen of patients with OA flare pain (hip or knee) significantly reduced mean baseline pain intensity scores from 2.4 ± 0.5 to 1.3 at the final visit compared to placebo (P < 0.001) on a 4-point scale (from 0 = none to 3 = severe) [96]. Treatment-related adverse events occurred in 24.4% patients receiving tramadol/paracetamol and in 8.1% of placebo patients; withdrawal due to adverse events was reported for 12.7% patients on fixed-dose combination and 5.4% of placebo patients. Tramadol/paracetamol also provided significantly superior pain relief compared to placebo (P = 0.019) in the subgroup of 113 elderly patients [100].

Patients with knee or hip OA and with at least moderate pain (>69 mm in a 100 mm VAS scale) despite treatment with stable doses of celecoxib or rofecoxib received tramadol/paracetamol or placebo as add-on therapy for 3 months [97]. Pain intensity scores following combination treatment were significantly lower than those for placebo (41.5 ± 26 versus 48.3 ± 26.6, P = 0.025). Improvement in WOMAC physical function was also significantly better than that in the placebo group (P = 0.049). Withdrawal due to adverse events occurred in 13.1% tramadol/paracetamol and 3.9% placebo patients. No serious adverse events occurred that were related to the study medication.

Korean patients with knee OA and moderate pain despite stable doses of meloxicam or aceclofenac received add-on treatment with tramadol/paracetamol for 4 weeks [98]. All patients with reduced pain (<4 on the NRS) were then randomized to monotherapy of either tramadol/paracetamol or NSAID treatment for a further 8 weeks. The 97 patients with significant pain reduction and significant improvements of the WOMAC OA index score (both P < 0.0005) following the 4-week add-on therapy maintained their pain-improved state with either agent for the next 8 weeks. One tramadol/paracetamol patient withdrew due to adverse events.

A second Korean study investigated the effect of tramadol/paracetamol titration on the development of adverse events in patients with knee OA on stable NSAID therapy [99]. Patients were randomized to either one 37.5 mg tramadol/325 mg paracetamol tablet tid for 2 weeks or titration to this dose over 7 days. The discontinuation rate due to adverse events was significantly lower in the titration group (10.5% versus 26.2% for nontitration, P < 0.001).

In all studies, the most common treatment-related adverse events were nausea, vomiting, constipation, dizziness, and somnolence. These adverse effects can be avoided in the majority of patients with a thorough titration of tramadol/paracetamol.

These studies suggest the effectiveness of tramadol/paracetamol as an add-on option to NSAIDs in the...
management of OA pain. However, in light of today’s knowledge about NSAIDs, long-term treatment with NSAIDs cannot be considered safe any longer and maintenance treatment with tramadol/paracetamol with NSAIDs for flares is likely the safer option.

5.1.2. Low Back Pain. Low back pain is very common and is nonspecific for the majority of patients [101]. It can arise from many different causes and can comprise both nociceptive and neuropathic mechanisms [102]. A multimodal and individualized treatment approach is therefore required [103]. Both the ACPC/APS and NICE guidelines recommend physical activity and exercise, manual therapy (including spine manipulation), acupuncture, and cognitive-behavioral therapy as nonpharmacological options [104, 105]. According to the NICE guidelines, pharmacological treatment should start with paracetamol followed by NSAIDs (combined with a proton pump inhibitor in persons >45 years) and/or weak opioids (which seem to include fixed-dose combinations) [105]. TCA s can be offered if these medications are insufficient but SSRIs are not recommended. Strong opioids can be given in the short-term for severe pain. Paracetamol and NSAIDs provide pain relief for nociceptive pain but are largely ineffective in neuropathic pain [21]. A combination of treatments is therefore often required to manage both components of chronic low back pain [103].

The efficacy of tramadol/paracetamol for the treatment of chronic low back pain was assessed in two studies [106, 107]. Both were double-blind, randomized studies in patients with at least moderate chronic lower back pain receiving either fixed-dose combination treatment or placebo over a 3-month period.

In the first study, patients had a mean baseline pain score (100 mm VAS pain scale) of 71.1 mm (tramadol/paracetamol group) and 68.8 mm (placebo group) [106]. Combination treatment significantly improved pain scores (to 44.4 mm versus 52.3 mm for placebo, \( P = 0.015 \)) compared to placebo and provided better pain relief (\( P < 0.001 \)) and improved scores on measures of functioning and quality of life. Cumulative incidence of discontinuation due to insufficient pain relief was significantly lower for the combination product (22.1% versus 41% for placebo, \( P < 0.001 \)). Treatment-related adverse events were reported for 23.6% of tramadol/paracetamol and 3.8% placebo patients with discontinuation rates due to adverse events more frequently observed for the active agent (18.6% versus 5.7%).

The mean baseline pain score of the patients included in the second study was 68 mm [107]. Tramadol/paracetamol treatment reduced pain more effectively than placebo (final pain scores 47 mm versus 63 mm, \( P < 0.001 \)) and improved quality of life and emotional and mental health. The withdrawal rate due to adverse events was 28.1% for tramadol/paracetamol and 7.6% for placebo. Main treatment-related adverse events in the combination group were nausea (12%), dizziness (10.8%), and constipation (10.2%).

In summary, the two studies show moderate benefits of tramadol/paracetamol treatment compared to placebo for patients with chronic low back pain over a 3-month period. However, a multimodal approach is often required to achieve adequate pain relief.

5.1.3. Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common inflammatory disease characterized by persistent synovitis, systemic inflammation, and autoantibodies [111]. The etiology is multifactorial; prevalence rises with age and is highest in elderly women [111]. Besides the destruction of cartilage and underlying bone, RA often leads to cardiovascular and other comorbidities. Disease-modifying antirheumatic drugs are the mainstay of RA treatment but analgesics are commonly required from the very beginning to control pain. NSAIDs are recommended for pain management in early arthritis after careful evaluation of gastrointestinal, renal, and cardiovascular status [112] and in a stepped approach coprescribed with a proton pump inhibitor in the short-term [113] but are not appropriate for long-term disease control [81, 112, 113]. Analgesics such as paracetamol, codeine, or fixed-dose combinations are recommended to potentially reduce the need for long-term NSAID or COX-2 inhibitor treatment [81].

The administration of tramadol/paracetamol in RA pain was investigated in one study. Patients with RA pain inadequately controlled by NSAIDs and disease-modifying antirheumatic drugs received one tramadol/paracetamol tablet tid or matching placebo for one week as add-on to their treatment regimen [108]. Mean pain intensity (100 mm VAS scale) at baseline was 60.2 ± 14.5 mm for the combination and 61.3 ± 17.6 mm for placebo and improved significantly more in the tramadol/paracetamol group (47.2 ± 20 mm versus 53.8 ± 16.6 mm for placebo; \( P = 0.018 \)). Mean daily pain relief scores were also significantly greater (\( P = 0.037 \)) but physical function did not differ between the groups. Adverse events (57.6% versus 22.4% for placebo) and discontinuations due to adverse events (19% versus 3%) were significantly more common in the active group (\( P < 0.001 \)). This study indicates some short-term efficacy of tramadol/paracetamol in RA pain management. In light of the long-term safety problems with NSAIDs, alternative long-term maintenance treatment with tramadol/paracetamol accompanied by add-on NSAIDs treatment for flares should be investigated in further studies.

5.2. Painful Diabetic Polyneuropathy (DPN). Diabetic polyneuropathy is a frequent long-term complication of diabetes. In approx. 6% of type 1 and 18% of type 2 diabetic patients, this condition is associated with neuropathic pain which has a profound impact on quality of life [114]. Traditional analgesics such as paracetamol and NSAIDs are largely ineffective in all types of neuropathic pain [21]. There are a number of guidelines available, and the ones published in the last two years were recently summarized and compared [115]. According to this paper, all guidelines recommend TCAs and duloxetine as first-line agents except for the American Academy of Neurology (AAN) guidelines which recommend only pregabalin [116]. Additional first-line medications according to the European Federation of Neurological Societies (EFNS) guidelines are gabapentin, pregabalin, and venlafaxine [117].

Two studies have assessed the efficacy of tramadol/paracetamol for painful DPN [109, 110]. In the first study,
diabetic patients (94% type 2) with daily painful DPN in the lower extremities for the past 3 months received tramadol/paracetamol or placebo for 66 days [109]. Patients presented with average daily pain scores of 7.1 ± 1.4 and 7.1 ± 1.3, respectively (11-point NRS scale). Supplemental paracetamol use was permitted during the treatment phase but could not exceed 4 g daily from all sources. Treatment with tramadol/paracetamol reduced the average daily pain more effectively than placebo (−2.71 versus −1.83, \( P = 0.001 \)) with a greater number of treatment responders (≥50% pain reduction: 37.5% versus 21.9%, \( P = 0.003 \)). Significantly greater improvements than placebo were also observed for further pain measures, sleep interference, global impression, and several quality of life measures and mood. The adverse event rate was similar for both groups with nausea (11.9% versus 3.3%), dizziness, and somnolence (both 6.3% versus 1.3%) more common under combination treatment.

The second study compared the efficacy of tramadol/paracetamol and gabapentin in type 2 diabetes with painful symmetric neuropathy in the lower limbs [110]. Mean pain intensity was reduced with no significant difference between treatments (\( P = 0.744 \)). Improvements in further pain measures, sleep interference, and quality of life were comparable between groups. The incidence of adverse events was not significantly different between treatments except for nausea/vomiting (8.9% tramadol/paracetamol, 1.2% gabapentin, \( P = 0.03 \)), and similar withdrawal rates due to adverse events were reported (13.9% versus 13.1%).

Overall, the two studies suggest that fixed-dose tramadol/paracetamol is well tolerated and leads to pronounced pain relief in the treatment of painful DPN.

5.3. Elderly Patients. Pain is a common occurrence in elderly patients living in the community. Most elderly patients (85%) experience moderate or severe pain; for a third of them this pain is continuous [14]. Musculoskeletal pain is the predominant type of pain. Pain is often underrecognized and undertreated with significant consequences for mobility, mood, restrictions in daily activities, and social activities which can all greatly affect quality of life. Pain management is challenging. Elderly patients often suffer from comorbidities and require various medications, which could increase the risk of drug-drug interactions and limit the range of drugs appropriate for treatment. Pharmacokinetic and metabolic changes with advancing age resulting in different drug sensitivities compared to younger patients also need to be considered when prescribing medication. The recently updated Beers criteria for potentially inappropriate medication use in older adults provide the family practitioner with information and recommendations for different medication classes including pain medication [75]. Caution is advised when prescribing NSAIDs; the American Geriatrics Society recommends to consider NSAIDs "rarely, with extreme caution, in highly selected individuals" and to avoid their use in patients ≥75 years of age [49].

The efficacy and safety of tramadol/paracetamol fixed-dose combination were assessed in a subset of patients ≥65 years of age with OA flare pain in a placebo-controlled, randomized study [100] and in elderly patients with predominantly musculoskeletal pain participating in the larger-scale noninterventional, observational SALZA study [87]. Both studies were described previously; both showed that tramadol/paracetamol was efficacious with a good safety profile for the elderly participants. Older patients (≥75 years old) in the observational ELZA study also showed significantly reduced pain intensity following treatment with the fixed-dose combination; 65.1% reported important or complete pain relief [86]. For patients aged over 75 years, the minimum interval between doses should be not less than 6 hours, due to the presence of tramadol [118].

6. Conclusions

(i) Pain is one of the major reasons for patients to consult their family practitioner.

(ii) The family practitioner plays an important role in the prevention, diagnosis, and early management of chronic pain and should be at the core of the multidisciplinary team for pain management.

(iii) The diagnostic work-up of pain should include quality of life parameters and an evaluation of the specific situation of the patient.

(iv) The goal of pain management is not only pain relief, but also should include improvements in restrictions of daily activities and social life and in quality of life to increase the overall well-being of the patient.

(v) Long-term treatment of chronic pain is often associated with safety and tolerability issues and must be individualized for each patient.

(vi) NSAIDs are useful short-term analgesics but are associated with gastrointestinal, cardiovascular, and renal side effects and mortality. Their long-term use in the management of chronic pain needs to be carefully weighted against potential side effects.

(vii) Pain is often multimechanistic. Fixed-dose combination analgesics combine compounds with different mechanisms of action and might thereby be useful in the treatment of multimechanistic pain. They might provide a broader analgesic spectrum, potentially synergistic analgesic efficacy, and an improved benefit/risk ratio.

(viii) Analgesic synergy was demonstrated for the fixed-dose combination tramadol/paracetamol. The combination was effective in a variety of different pain conditions frequently encountered by the family practitioner and showed good tolerability.

(ix) Tramadol/paracetamol might be considered in particular in elderly patients as an alternative to conventional analgesics such as NSAIDs, which should be used rarely with extreme caution in this population.

(x) However, studies are required to investigate the long-term use of fixed-dose combinations.
Disclosure

I. Morón Merchante received consultancy honoraria from Boehringer Ingelheim, Grünenthal GmbH, Merck Sharp & Dohme Corporation, and Takeda Pharmaceuticals Europe and has received lecture fees from Almirall, Astra-Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Esteve, Grünenthal GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corporation, Novartis, and Sanofi-Aventis. J. V. Pergolizzi received consultancy honoraria from Grünenthal GmbH, Baxter, Endo Pharmaceuticals, and Hospira. M. van de Laar received consultancy honoraria from Merck The Netherlands, Pfizer Europa and Grünenthal GmbH, and speaker honoraria from Pfizer Europa. H. U. Mellinghoff received consultancy honoraria from Grünenthal GmbH. S. Nalamachu has received consultancy honoraria or research grants from the following companies in the past five years: Grünenthal GmbH; Johnson and Johnson, Endo Pharmaceuticals, Cephalon, Alphapharma, King Pharmaceuticals, Allergan, ProStakan, and Covidien. J. O’Brien received consultancy honoraria from Grünenthal GmbH. S. Perrot received consultancy honoraria from Grünenthal GmbH. R. B. Raffa is a speaker, consultant, and/or basic science investigator for several pharmaceutical companies involved in analgesic research, but receives no royalty (cash or otherwise) from the sale of any product; he received consultancy honoraria from Grünenthal GmbH.

Acknowledgments

The meeting was supported by Grünenthal GmbH, Aachen, Germany. The authors were compensated for their participation in the consensus meeting but did not receive honoraria for the jointly agreed statements and their work on the paper. The authors acknowledge the writing and editorial assistance from Birgit Brett and Elke Grosselindemann (Brett Medical Writing Germany/Australia). All costs associated with the publication of the paper were met by Grünenthal GmbH, Aachen, Germany.

References

[1] C. H. Friessem, A. Willweber-Strumpf, and M. W. Zenz, “Chronic pain in primary care. German figures from 1991 and 2006,” BMC Public Health, vol. 9, article 299, 2009.
[2] P. Mäntyselkä, E. Kumpusalo, R. Ahonen et al., “Pain as a reason to visit the doctor: a study in Finnish primary health care,” Pain, vol. 89, no. 2-3, pp. 175–180, 2001.
[3] K. J. Reid, J. Harker, M. M. Bala et al., “Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact,” Current Medical Research and Opinion, vol. 27, no. 2, pp. 449–462, 2011.
[4] H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Galagher, “Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment,” European Journal of Pain, vol. 10, no. 4, pp. 287–333, 2006.
[5] P. C. Langlely, “The prevalence, correlates and treatment of pain in the European Union,” Current Medical Research and Opinion, vol. 27, no. 2, pp. 463–480, 2011.
[6] Institute of Medicine Report from the Committee on Advancing Pain Research, Care, Education, Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research, The National Academies Press, 2011.
[7] D. Schopflocher, P. Taenzer, and R. Jovey, “The prevalence of chronic pain in Canada,” Pain Research & Management, vol. 16, no. 6, pp. 445–450, 2011.
[8] C. Toth, J. Lander, and S. Wiebe, “The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population,” Pain Medicine, vol. 10, no. 5, pp. 918–929, 2009.
[9] M. Blyth, L. M. March, A. J. M. Bnabic, L. R. Jorm, M. Williamson, and M. J. Cousins, “Chronic pain in Australia: a prevalence study,” Pain, vol. 89, no. 2-3, pp. 127–134, 2001.
[10] C. H. Dominick, F. M. Blyth, and M. K. Nicholas, “Unpacking the burden: understanding the relationships between chronic pain and comorbidity in the general population,” Pain, vol. 153, no. 2, pp. 293–304, 2012.
[11] P. Langley, G. Müller-Schwefe, A. Nicolau, H. Liedgens, J. Pergolizzi, and G. Varrassi, “The societal impact of pain in the European Union; health-related quality of life and healthcare resource utilization,” Journal of Medical Economics, vol. 13, no. 3, pp. 571–581, 2010.
[12] P. Langley, G. Müller-Schwefe, A. Nicolau, H. Liedgens, J. Pergolizzi, and G. Varrassi, “The impact of pain on labor force participation, absenteeism and presenteeism in the European Union,” Journal of Medical Economics, vol. 13, no. 4, pp. 662–672, 2010.
[13] U. Jakobsson, “The epidemiology of chronic pain in a general population: results of a survey in southern Sweden,” Scandinavian Journal of Rheumatology, vol. 39, no. 5, pp. 421–429, 2010.
[14] S. T. Brown, M. K. Kirkpatrick, M. S. Swanson, and I. L. McKenzie, “Pain experience of the elderly,” Pain Management Nursing, vol. 12, no. 4, pp. 190–196, 2011.
[15] R. Baron, A. Binder, and G. Wasner, “Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment,” The Lancet Neurology, vol. 9, no. 8, pp. 807–819, 2010.
[16] R. H. Dworkin, D. C. Turk, J. T. Farrar et al., “Core outcome measures for chronic pain clinical trials: IMMPACT recommendations,” Pain, vol. 113, no. 1-2, pp. 9–19, 2005.
[17] D. Wilson and M. J. Hockenberry, Wong’s Clinical Manual of Pediatric Nursing, Elsevier Mosby, St Louis, Mo, USA, 8th edition, 2008.
[18] R. Freynhagen, R. Baron, U. Gockel, and T. R. Tölle, “painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain,” Current Medical Research and Opinion, vol. 22, no. 10, pp. 1911–1920, 2006.
[19] D. Bouhassira, N. Attal, H. Alchaar et al., “Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4),” Pain, vol. 114, no. 1-2, pp. 29–36, 2005.
[20] M. Bennett, “The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs,” Pain, vol. 92, no. 1-2, pp. 147–157, 2001.
[21] M. L. Haanpää, M. M. Backonja, M. J. Bennett et al., “Assessment of neuropathic pain in primary care,” American Journal of Medicine, vol. 122, no. 10, supplement, pp. S13–S21, 2009.
[22] International Association for the Study of Pain, “Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy,” Pain, vol. 3, supplement, pp. S1–S226, 1986.
[23] H. Merskey and N. Bogduk, Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definitions of Pain Terms, IASP Press, Seattle, WA, USA, 1994.

[24] N. Schmitt and H. U. Gerbershagen, "The Mainz Staging System (MPSS) for chronic pain," Pain, vol. 41, supplement 5, p. S484, 1990.

[25] German Pain Questionnaire, 2012, http://www.dgss.org/deutscherschmerzfragebogen/.

[26] J. Pergolizzi, K. Ashbeck, D. Aldington et al., "The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors?" Current Medical Research and Opinion, vol. 28, no. 2, pp. 249–256, 2012.

[27] B. Collett, "The burden of chronic pain," Current Medical Research and Opinion, vol. 27, pp. 2065–2066, 2011.

[28] J. E. Ware Jr. and C. D. Sherbourne, "The MOS 36-item short-form health survey (SF-36)—I. Conceptual framework and item selection," Medical Care, vol. 30, no. 6, pp. 473–483, 1992.

[29] S. H. Lovibond and P. F. Lovibond, Manual for the Depression Anxiety Stress Scales, Psychology Foundation, Sydney, Australia, 2nd edition, 1995.

[30] A. T. Beck, W. Y. Rial, and K. Rickels, "Short form of depression inventory: cross validation," Psychological Reports, vol. 34, no. 3, pp. 1184–1186, 1974.

[31] N. Bellamy, W. W. Buchanan, C. H. Goldsmith, J. Campbell, and L. W. Stitt, "Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee," Journal of Rheumatology, vol. 15, no. 12, pp. 1833–1840, 1988.

[32] N. Bellamy, WOMAC Osteoarthritis Index: User Guide IX, Queensland, Brisbane, Australia, 2009.

[33] G. Müller-Schwee, W. Jaksch, B. Morlion et al., "Make a CHANGE: optimising communication and pain management decisions," Current Medical Research and Opinion, vol. 27, no. 2, pp. 481–488, 2011.

[34] J. E. Ware, M. Kosinski, and S. D. Keller, "A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity," Medical Care, vol. 34, no. 3, pp. 220–233, 1996.

[35] R. Melzack, "The short-form McGill Pain Questionnaire," Pain, vol. 30, no. 2, pp. 191–197, 1987.

[36] C. S. Cleeland and K. M. Ryan, "Pain assessment: global use of the Brief Pain Inventory," Annals of the Academy of Medicine Singapore, vol. 23, no. 2, pp. 129–138, 1994.

[37] The EuroQol Group, "EuroQol—a new facility for the measurement of health-related quality of life," Health Policy, vol. 16, pp. 199–208, 1990.

[38] K. D. Brandt, S. A. Mazzuca, and K. A. Buckwalter, "Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees," Rheumatology, vol. 45, no. 11, pp. 1389–1394, 2006.

[39] J. Flood, "The role of acetaminophen in the treatment of osteoarthritis," The American Journal of Managed Care, vol. 16, pp. S48–S54, 2010.

[40] H. S. Smith, "Potential analgesic mechanisms of acetaminophen," Pain Physician, vol. 12, no. 1, pp. 269–280, 2009.

[41] W. Zhang, G. Nuki, R. W. Moskowitz et al., "OARSI recommendations for the management of hip and knee osteoarthritis—part III: changes in evidence following systematic cumulative update of research published through January 2009," Osteoarthritis and Cartilage, vol. 18, no. 4, pp. 476–499, 2010.

[42] A. Schilling, R. Corey, M. Leonard, and B. Eighesad, "Acetaminophen: old drug, new warnings," Cleveland Clinic Journal of Medicine, vol. 77, no. 1, pp. 19–27, 2010.

[43] W. M. Lee, "Etiologies of acute liver failure," Seminars in Liver Disease, vol. 28, no. 2, pp. 142–152, 2008.

[44] FDA, "Assessment of safety of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)," 2012, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882B2_02_McNeil-NSAID.htm.

[45] Electronic medicines compendium, "Diclofenac sodium 50 mg tablets," 2012, http://www.medicines.org.uk/emc/medicine/22653#INCOMPATIBILITIES.

[46] Electronic Medicines Compendium, "Anadin ibuprofen 200 mg tablets," 2012, http://www.medicines.org.uk/emc/medicine/15681/SPC/Anadin+Ibuprofen+200mg+Tablets/.

[47] Electronic Medicines Compendium, "Naproxen 250 mg tablets," 2012, http://www.medicines.org.uk/emc/medicine/23037/SPC#INCOMPATIBILITIES.

[48] Electronic Medicines Compendium, "Celebrex 100 mg & 200 mg capsules," 2012, http://www.medicines.org.uk/emc/medicine/14534#INCOMPATIBILITIES.

[49] American Geriatrics Society Panel, "Pharmacological management of persistent pain in older persons," Journal of the American Geriatrics Society, vol. 57, no. 8, pp. 1331–1346, 2009.

[50] E. Kalso, J. E. Edwards, R. A. Moore, and H. J. McQuay, "Opioids in chronic non-cancer pain: systematic review of efficacy and safety," Pain, vol. 112, no. 3, pp. 372–380, 2004.

[51] M. Camilleri, "Opioid-induced constipation: challenges and therapeutic opportunities," American Journal of Gastroenterology, vol. 106, no. 5, pp. 835–842, 2011.

[52] M. Korkmazsky, J. Ghanehadi, A. Sanchez, H. M. Lin, and M. Pappagal, "Feasibility study of rapid opioid rotation and titration," Pain Physician, vol. 14, no. 1, pp. 71–82, 2011.

[53] C. Passero and M. McCaffery, "Opioid-induced hyperalgesia," Journal of Perianesthesia Nursing, vol. 27, no. 1, pp. 46–50, 2012.

[54] J. Bacha, S. Reast, and A. Pearlstone, "Treatment practices and perceived challenges for European physicians treating opioid dependence," Heroin Addiction and Related Clinical Problems, vol. 12, no. 3, pp. 9–19, 2010.

[55] D. H. Angres and K. Bettinardi-Angres, "The disease of addiction: origins, treatment, and recovery," Disease-a-Month, vol. 54, no. 10, pp. 696–721, 2008.

[56] W. Ling, L. Mooney, and M. Hillhouse, "Prescription opioid abuse, pain and addiction: clinical issues and implications," Drug and Alcohol Review, vol. 30, no. 3, pp. 300–305, 2011.

[57] J. P. Schneider, M. Matthews, and R. N. Jamison, "Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?" CNS Drugs, vol. 24, no. 10, pp. 805–810, 2010.

[58] R. B. Raffa and J. V. Pergolizzi, "Opioid formulations designed to resist/deter abuse," Drugs, vol. 70, no. 13, pp. 1657–1675, 2010.

[59] J. Pergolizzi, R. H. Böger, K. Budd et al., "Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)," Pain Practice, vol. 8, no. 4, pp. 287–313, 2008.

[60] R. B. Raffa and E. Friderics, "The basic science aspect of tramadol hydrochloride," Pain Reviews, vol. 3, no. 4, pp. 249–271, 1996.
[61] R. B. Raffa, R. J. Tallarida, R. Taylor Jr., and J. V. Pergolizzi Jr., “Fixed-dose combinations for emerging treatment of pain,” Expert Opinion on Pharmacotherapy, vol. 13, no. 9, pp. 1261–1270, 2012.

[62] E. A. Shipton, “Tramadol—present and future,” Anaesthesia and Intensive Care, vol. 28, no. 4, pp. 363–374, 2000.

[63] W. Leppert and J. Łuczak, “The role of tramadol in cancer pain treatment—a review,” Supportive Care in Cancer, vol. 13, no. 1, pp. 5–17, 2005.

[64] J. V. Pergolizzi Jr., R. Taylor Jr., and R. B. Raffa, “Extended-release formulations of tramadol in the treatment of chronic pain,” Expert Opinion on Pharmacotherapy, vol. 12, no. 11, pp. 1757–1768, 2011.

[65] Electronic Medicines Compendium, “Tramadol hydrochloride 50 mg capsules,” 2012, http://www.medicines.org.uk/emc/medicines/24186/SPC tramadol%20hydrochloride%2050mg%20capsules/.

[66] L. J. Scott and C. M. Perry, “Tramadol: a review of its use in perioperative pain,” Drugs, vol. 60, no. 1, pp. 139–176, 2000.

[67] L. L. Jorge, C. C. Feres, and V. E. P. Teles, “Topical preparations for pain relief: efficacy and patient adherence,” Journal of Pain Research, vol. 4, pp. 11–24, 2011.

[68] G. Mick and G. Correa-Illanes, “Topical pain management with the 5% lidocaine medicated plaster—a review,” Current Medical Research and Opinion, vol. 28, no. 6, pp. 937–951, 2012.

[69] S. Derry, R. A. Moore, and R. Rabbie, “Topical NSAIDs for chronic musculoskeletal pain in adults,” Cochrane Database of Systematic Reviews, vol. 9, Article ID CD007400, 2012.

[70] P. Anand and K. Bley, “Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch,” British Journal of Anaesthesia, vol. 107, no. 4, pp. 490–502, 2011.

[71] M. L. Haanpää, G. K. Gourlay, J. L. Kent et al., “Treatment considerations for patients with neuropathic pain and other medical comorbidities,” Mayo Clinic Proceedings, vol. 85, no. 3, supplement, pp. S15–S25, 2010.

[72] G. J. Sills, “Mechanisms of action of antiepileptic drugs,” in Epilepsy 2011: From Science to Society. A Practical Guide to Epilepsy, J. W. Sander, M. C. Walker, and J. E. Smalls, Eds., ILAE, National Society for Epilepsy, London, UK, 2011.

[73] M. D. Sullivan and J. P. Robinson, “Antidepressant and anticonvulsant medication for chronic pain,” Physical Medicine and Rehabilitation Clinics of North America, vol. 17, no. 2, pp. 381–400, 2006.

[74] R. H. Dworkin, A. B. O’Connor, J. Audette et al., “Recommendations for the pharmacological management of neuropathic pain: an overview and literature update,” Mayo Clinic Proceedings, vol. 85, supplement 3, pp. S3–S14, 2010.

[75] American Geriatrics Society 2012 Beers Criteria Update Expert Panel, “American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults,” Journal of the American Geriatrics Society, vol. 60, no. 4, pp. 616–631, 2012.

[76] F. Buttgereit, G. R. Burmester, R. H. Straub, M. J. Seibel, and H. Zhou, “Exogenous and endogenous glucocorticoids in rheumatic diseases,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 1–9, 2011.

[77] J. M. Grossman, R. Gordon, V. K. Ranganath et al., “American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis,” Arthritis Care & Research, vol. 62, no. 11, pp. 1515–1526, 2010.

[78] D. Franchimont, “Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies,” Annals of the New York Academy of Sciences, vol. 1024, pp. 124–137, 2004.

[79] D. Huscher, K. Thiele, E. Grommica-Ihle et al., “Dose-related patterns of glucocorticoid-induced side effects,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1119–1124, 2009.

[80] M. C. Lansang and L. Kramer Hustak, “Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them,” Cleveland Clinic Journal of Medicine, vol. 78, no. 11, pp. 748–756, 2011.

[81] NICE, “Rheumatoid arthritis: the management of rheumatoid arthritis in adults,” NICE, London, UK, 2009, http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf.

[82] S. Perrot, D. Krause, P. Crozes, and C. Naim, “Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study,” Clinical Therapeutics, vol. 28, no. 10, pp. 1592–1606, 2006.

[83] N. Rawal, V. Macquaire, E. Catala, M. Berti, R. Costa, and M. Wietlisbach, “Tramadol/paracetamol combination tablet for postoperative pain following ambulatory hand surgery: a double-blind, double-dummy, randomized, parallel-group trial,” Journal of Pain Research, vol. 4, pp. 103–110, 2011.

[84] J. Filitz, H. Ihmsen, W. Günther et al., “Supra-additive effects of tramadol and acetaminophen in a human pain model,” Pain, vol. 136, no. 3, pp. 262–270, 2008.

[85] W. S. Mullican and J. R. Lacy, “Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial,” Clinical Therapeutics, vol. 23, no. 9, pp. 1429–1445, 2001.

[86] A. Serrie, H. Ganry, A. Creuzé, and B. Schatz, “Epidemiological data, efficacy and safety on a fixed combination of paracetamol (325 mg) and tramadol (37.5 mg) in the treatment of moderate to severe pain, in general practice (ELZa survey: Efficacite et To Lerance de ZAldiar),” Journal of Applied Therapeutic Research, vol. 8, no. 1, pp. 3–14, 2011.

[87] O. Mejjad, A. Serrie, and H. Ganry, “Epidemiological data, efficacy and safety of a paracetamol-tramadol fixed combination in the treatment of moderate-to-severe pain. SALZA: a post-marketing study in general practice,” Current Medical Research and Opinion, vol. 27, no. 5, pp. 1013–1020, 2011.

[88] L. Alwine, “Long-term (2-year) analgesic efficacy of tramadol/acetaminophen tablets,” Nice, France, European League Against Rheumatism (EULAR) Congress, 2000.

[89] L. Busija, L. Bridgett, S. R. M. Williams et al., “Osteoarthritis,” in Best Practice and Research: Clinical Rheumatology, vol. 9, Article ID CD007400, 2012.

[90] M. D. Sullivan and J. P. Robinson, “Antidepressant and anticonvulsant medication for chronic pain,” Physical Medicine and Rehabilitation Clinics of North America, vol. 17, no. 2, pp. 381–400, 2006.

[91] R. H. Dworkin, A. B. O’Connor, J. Audette et al., “Recommendations for the pharmacological management of neuropathic pain: an overview and literature update,” Mayo Clinic Proceedings, vol. 85, supplement 3, pp. S3–S14, 2010.

[92] American Geriatrics Society 2012 Beers Criteria Update Expert Panel, “American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults,” Journal of the American Geriatrics Society, vol. 60, no. 4, pp. 616–631, 2012.

[93] F. Buttgereit, G. R. Burmester, R. H. Straub, M. J. Seibel, and H. Zhou, “Exogenous and endogenous glucocorticoids in rheumatic diseases,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 1–9, 2011.

[94] J. M. Grossman, R. Gordon, V. K. Ranganath et al., “American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis,” Arthritis Care & Research, vol. 62, no. 11, pp. 1515–1526, 2010.
R. Chou, A. Qaseem, V. Snow et al., “Diagnosis and treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study,” Clinical Therapeutics, vol. 25, no. 4, pp. 1123–1141, 2003.

P. M. Pelosi, L. Fortin, A. Beaulieu, M. Kamin, and N. R. Rosenthal, “Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double-blind, placebo controlled trial,” Journal of Rheumatology, vol. 31, no. 12, pp. 2454–2463, 2004.

E. Y. Lee, E. B. Lee, B. J. Park et al., “Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial,” Clinical Therapeutics, vol. 28, no. 12, pp. 2052–2060, 2006.

R. Freeman, P. Raskin, D. J. Hewitt et al., “Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 147–161, 2007.

S. H. Ko, H. S. Kwon, J. M. Yu et al., “Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy,” Diabetic Medicine, vol. 27, no. 9, pp. 1033–1040, 2010.

D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010.

B. Combe, R. Landewe, C. Lukas et al., “EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT),” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 34–45, 2007.

R. Luqumani, S. Hennell, C. Estrach et al., “British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years),” Rheumatology, vol. 48, no. 4, pp. 436–439, 2009.

K. Van Acker, D. Bouhassira, D. De Bacquer et al., “Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics,” Diabetes and Metabolism, vol. 35, no. 3, pp. 206–213, 2009.

V. Spallone, “Management of painful diabetic neuropathy: guideline guidance or jungle?,” Current Diabetes Reports, vol. 12, pp. 403–413, 2012.

V. Bril, J. D. England, G. M. Franklin et al., “Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American Association of Neuromuscular and Electrophysiologic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation,” Muscle and Nerve, vol. 43, no. 6, pp. 910–917, 2011.

N. Attal, G. Cruccu, R. Baron et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” European Journal of Neurology, vol. 17, no. 9, pp. 1113–1123, 2010.

ZALDIAR film-coated tablets, “Summary of Product Characteristics,” 2012, http://www.grunenthal.com/grt-web/Grunenthal_Group/Products/Zaldiari_j116100142.jsp.

Reference materials: